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ABSTRACT 
 
HIV is a highly mutable virus that has become a global pandemic.  In order to prevent 
further spread of this disease a topical microbicide that is cheap and easy to administer and 
produce is necessary. Our project involved the extraction of the HIV drug Nevirapine from 
commercial tablets to encapsulate it inside glucan particles for mucosal delivery.  Glucan 
Particles (GP) are naturally internalized by macrophages and Langerhans cells thought to be the 
first cells to be HIV infected at mucosal sites. GP are hollow microparticles derived from baker’s 
yeast that can be used to absorb the Nevirapine into an encapsulated core.   To keep the drug 
trapped inside the core various synthetic strategies were evaluated to identify an effective 
formulation for future in vitro and in vivo testing. 
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BACKGROUND 
 
Since 1981, acquired immunodeficiency syndrome (AIDS) has been a pandemic affecting 
millions of people in countries all over the world.  Through years of research, scientists now 
know that "AIDS is caused by infection with a virus called human immunodeficiency virus 
(HIV)” (CDC).  HIV is a lentivirus, which is part of a larger group of viruses called retroviruses. 
Lentiviruses are categorized by the fact that they are slow to fully infect and thus take a long 
time to produce lasting negative side effects in the body.  HIV interacts with the primary cell 
surface receptor CD4+ to gain entry into white T cells. These cells are crucial to fighting off 
infections within the body, and when they are destroyed, the body is left vulnerable to other 
infections and diseases.  A person infected with HIV can carry the disease and never develop any 
serious side effects until the number of T cells with CD4+ receptors in their body has greatly 
decreased.  HIV is a very dangerous virus due to the fact that it can mutate readily, and one 
person can be infected with different strains of HIV at the same time.  HIV can only replicate 
within cells, and it directly attacks the immune system. Worldwide at the end of 2008, there were 
a reported 33.4 million people living with HIV/AIDS, and since 1981 more than 25 million 
people have died from this virus. 
 
Origin of HIV 
 HIV is thought to be originally derived from Simian Immunodeficiency Virus (SIV) 
based on the discovery that many strains of SIV have a very strong resemblance to known HIV 
strains.  SIV affects monkeys and it is believed to have crossed species through zoonosis, which 
is a viral transfer between humans and animals. This transfer could have occurred if a human had 
consumed an infected monkey or had blood transferred from an infected animal into an open cut 
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or wound. The exact means of zoonotic transmission is unknown, but there are many theories 
circulating as to how humans became infected with this virus. Nevertheless, researchers have 
concluded that the virus originated in West Central Africa between 1915 and 1940 (Korber et al., 
2000). 
 
Types of HIV 
The two known types of HIV are HIV-1, which is the version of the virus that is 
predominantly known worldwide, and HIV-2, which is uncommon except in West Africa.  
Although HIV-2 is less easily transmitted, both can be contracted through sexual contact, blood 
transfusion, or from mother to child during pregnancy, childbirth or breastfeeding.  Both HIV 
viruses are believed to cause AIDS, and after infection the two types are virtually 
indistinguishable.  
HIV-1 is categorized into four groups and these groups are believed to represent four 
separate transmissions of SIV to humans (Figure 1). The major type of HIV-1 is group M, and 
this group is then broken down into 9 subgroups. These subgroups are all genetically distinct 
from one another, and can even recombine together to create new hybrid viruses. When two 
subgroups mix and can be seen in more than one person they are known as Circulating 
Recombinant Forms (CRFs) of the virus. 
 
Figure 1: Different Levels of HIV Classification ("HIV types, subtypes, groups & 
strains”, 2010) 
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Worldwide, the different subtypes are very unevenly distributed, but the most widespread 
of all the types are A and C.  Subtypes A and C are most commonly seen in Africa and India. 
Type C has also caused the worst epidemics and is responsible for nearly half of all HIV 
infections worldwide.  Subtype B is the most common form of the virus found in the Americas 
and in Europe ("HIV types, subtypes, groups & strains, 2010). It is believed by scientists that 
more combinations and mutations of the disease will continue to appear and that the different 
subtypes will spread to new areas globally as the HIV epidemic continues. If this happens it will 
make preventing and possibly stopping the spread of HIV much more difficult. 
 
HIV-1 
As stated before, HIV needs to infect cells within a living organism in order to start the 
transcription process to replicate itself. Outside of a cell, an HIV particle measures about 0.1 
microns. In comparison to the CD4+ white blood cells that it infects, an HIV particle has one 
seventieth the diameter and is so small that it can only be imaged with an electron microscope.  
 
Figure 2: Diagram of the HIV Virus (Brinkhof, 2010) 
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A viral envelope, a matrix and a viral core are the three elements that make up the basic 
structure of an HIV particle (Figure 2). Each of these components are made of specific proteins, 
and these are integral to the way a particle is able to function and protect itself in the human 
body. The viral core is at the center of an HIV particle and is also known as a capsid. The capsid 
contains two copies of positive RNA that code for the nine genes associated with HIV. This core 
also contains a pol gene which consists of reverse transcriptase, integrase and protease, which are 
the three factors necessary for HIV replication. The matrix surrounds the viral core and is 
responsible for maintaining the stability of the virus. The protein that makes up the capsid is p24, 
and the matrix protein is p17, and both of these are part of the Gag polyprotein which provides 
the basic physical structure of the virus. The viral envelope is the outer layer of the HIV particle, 
and from this layer complex HIV proteins protrude to form what appear to be spikes on the 
surface of the particles. These protein spikes are made from gp120 and gp41. The other parts of 
HIV’s genome are three transctivators and three regulators (Figure 3). The transctivators are Tat, 
Rev, and Vpr, which work to enhance gene expression by increasing levels of transcription, and 
giving HIV a structure that can more easily overtake its host’s defenses.  The regulators are Vif, 
Nef and Vpu which disrupt antiviral activity, allow replication of the virus, and enhance virion 
release. (Jia, 2010). 
 
Figure 3:  Diagram of the HIV Genome. (Costin, 2007) 
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HIV infects CD4+ cells by using these glycoprotein spikes to bind to the CD4 and fuse to 
the cell membrane.  Once fusion occurs, the particle releases its contents into the cell where the 
HIV enzyme reverse transcriptase converts viral RNA to DNA.  The DNA formed is then spliced 
into the human DNA by integrase which is another HIV enzyme and becomes proviral DNA.  
When a cell that contains a provirus is activated, the human body treats the HIV infected genes 
the same as normal genes, and converts the DNA to mRNA which is then transported out of the 
cell and used as a blueprint to continue producing more HIV. The strands of mRNA contain 
complete copies of HIV genetic material, and long strands are hydrolyzed by protease to form 
shorter pieces which are all able to form more mature viral cores. Once this begins occurring in 
the body, more and more cells are infected, and unless HIV is diagnosed the immune system will 
continue to become more compromised. 
Two cells particularly important in HIV transmission are macrophages and Langerhans 
cells.  Both types of cells are the initial targets of HIV and provide an efficient way for HIV to 
access T cells. Macrophages are large cells derived from white blood cells that are found in 
many different types of tissue. Macrophages work by digesting foreign microorganisms and 
damaged cells. It has actually been stated that macrophages “form a reservoir of HIV-1 in 
infected persons” (Groot et al., 2008).  HIV can be stored in macrophages because the virus 
assembles itself into a sort of intracellular compartment, and in some instances this protects the 
virus from being attacked by antibodies. Langerhans cells are dendritic cells that that are located 
in epithelia. Langerhans cells characteristically cluster with numerous different types of T cells 
and this is thought to be the main reason explaining why such a small amount of HIV can 
quickly replicate enough to infect a whole immune system. The site where Langerhans cells and 
T cells interact creates the perfect atmosphere for explosive and rapid HIV production. HIV is 
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thought to move from mucosal tissue to lymph nodes through transmission by Langerhans cells 
as well. Both of these cells are key reasons why HIV is able to access T cells which, in turn 
drastically decreases the efficiency of the immune system against infection. Based on this 
knowledge, it seems that these are areas that it may be beneficial to halt future HIV infections. 
 
HIV Medications 
The main treatment option after infection with HIV is antiretroviral drug treatment.  
Advances in this area have allowed for infected individuals to maintain fairly normal lives as 
long as the HIV drugs are taken every day.  Antiretroviral drugs work to keep the amount of HIV 
in the body at a minimal level, which in turn decreases the amount of damage and slows the 
weakening of the immune system. Although the drugs work to prevent HIV damage, the exact 
time to start treatment is debated due to adverse side effects of the drugs. Generally it is believed 
that treatment should not begin until the later stages of HIV infection. A CD4 test measures the 
number of helper T cells in a sample of blood. A person uninfected with HIV will normally have 
between 500 and 1200 cells/mm3. Since HIV decreases the amount of CD4 in the blood, 
guidelines have been set up to determine exactly what levels of CD4 are considered dangerous 
enough to start treatment. It is recommended that antiretroviral treatment being once an infected 
individual reaches a level of CD4 under 350.  
There are five groups of antiretroviral medications and each is classified by the way they 
attack HIV.  Since HIV can mutate so easily treatment of HIV usually consists of combination 
therapy which involves taking more than one drug at a time.  Combination therapy largely 
reduces the rate of HIV resistance to the drugs. The two most common groups of HIV drugs are 
Nucleoside Reverse Transcriptase Inhibitors (NRTIs) and Non-Nucleoside Nucleoside Reverse 
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Transcriptase Inhibitors (NNRTIs), and both of these are available in most countries. Both 
NRTIs and NNRTIs interfere with reverse transcriptase which inhibits HIV from replicating 
within the cells. There are many combinations of drugs but both the World Health Organization, 
and American guidelines recommend the use of at least one NNRTI in treatment. The WHO 
states that the first line of treatment should be one NNRTI and 2 NRTIs. American guidelines 
recommend one NNRTI or a protease inhibitor in combination with two NRTIs. The other types 
of medication include Protease Inhibitors, Fusion Inhibitors and Co-Receptor Inhibitors. All of 
these interact with HIV in a way that limits interaction between the virus and healthy cells.  
These also are able to interfere with the conformation of the virus which slows down the rate it 
can infect healthy cells.  
 
Nevirapine  
One NNRTI that has been on the market since 1996 is Nevirapine. This drug was 
developed by Boehringer Ingelheim Pharmaceuticals, Inc. (Hargrave et al., 1991).  Nevirapine 
was the first NNRTI approved by the FDA, and is considered a breakthrough in HIV treatment. 
This drug works to lower the viral load, or the amount of HIV, that is present in the blood.  Like 
other NNRTIs, Nevirapine attaches itself to the reverse transcriptase and hinders the virus’ 
ability to reproduce. Specifically the drug binds to heterodimeric HIV-1 reverse transcriptase and 
disrupts the catalytic site of the enzyme. Nevirapine also prevents viral RNA from being changed 
to DNA which also halts replication.  By limiting the amount of HIV in the blood, this drug 
works to maintain the amount of CD4 cells in the body. Studies on Nevirapine have shown that 
90% of Nevirapine taken orally is absorbed into the body, and after initial absorption the drug is 
widely distributed to nearly every tissue in the body.  Nevirapine must be taken in combination 
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with other medications in order to ensure it usefulness. It is not fully known how HIV-1 
eventually becomes resistant to Nevirapine, but it is believed that a single mutation of the reverse 
transcriptase may be adequate for HIV to develop a high level of resistance. Also Nevirapine has 
no known effects against HIV-2. 
 
Albumin Binding Capabilities  
HSA or human serum albumin is produced in the liver, and is the most abundant protein 
in blood plasma. It is known for its ability to bind to ligands, which includes some drugs.  Due to 
this knowledge, HSA was tested and now there is conclusive evidence to prove that HSA can 
actually bind to certain HIV medications.  There is “clear cut evidence for the allosteric 
inhibition of anti-HIV drug binding to HSA.” HSA is made of single non-glycosylated chains 
that contain three homologous domains. The structural organization of the protein is what creates 
all the binding sites for ligands.  
 Although the combination therapy offered from many anti-HIV drugs has improved 
mortality rates, there is potential for a new way to administer these drugs. “One of the most 
important factors affecting the distribution and the free, active concentration of many 
administered drugs is binding affinity for HSA” (Fanalli et al., 2007).  The interactions of plasma 
proteins with anti-HIV drugs can drastically increase the efficiency of these drugs. It has been 
discovered that at concentrations used in therapy, Nevirapine binds to HSA and increases the 
affinity of heme, which is the site of oxygen binding, for HSA.  Since Nevirapine is “a small 
hydrophobic butterfly-shaped ligand” (Fanalli et al., 2007) its size doesn’t limit its preferential 
binding capabilities.  
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Studies of the binding ability of different anti-HIV drugs to plasma proteins have shown 
that Nevirapine binds with ~70% efficiency to Human serum albumin (HSA).  Proteins like HSA 
that are present in plasma have strong ligand binding capacity to different groups. HSA binds 
drugs non-specifically or by interaction at any of seven binding sites with different affinity.  In 
the case of Nevirapine, it has been found that it binds effectively to the FA7 site, which has been 
identified as a preferential binding site for bulky, heterocyclic molecules (Fanali et al., 2007). In 
order to prove that Nevirapine could bind to FA7, which is also known as Sudlow’s site I, a 
docking analysis was performed.  Nevirapine has the potential to act as an allosteric effector and 
this characteristic allows the Nevirapine to easily bind to HSA. 
 
Figure 4: Structure of Nevirapine  
 
AIDS Vaccines and HIV Microbicides 
Due to the high level of variance between each of the strains of HIV, the development of 
any type of vaccine has proven to be quite challenging. Other challenges affecting the progress 
of vaccine development include a lack of knowledge on exactly how to protect the immune 
system from the virus, as well as a lack of relevant animal models that would predict similar 
responses of a vaccine in humans. Due to these factors, scientists have also been trying to 
develop HIV microbicides, which are antimicrobial products that would prevent HIV 
transmission through sexual contact.  In order for microbicides to work, they would employ 
mechanisms that either kill or inactivate pathogens, strengthen the body’s defenses, block 
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infection by creating a barrier between the pathogen and target cells, or by preventing infection 
from spreading from infected cells to healthy ones (Microbicides, 2010) (Figure 5). 
 
Figure 5: Depictions of the Ways HIV Medications  
Halt HIV Replication (McCormack, 2001) 
 
Another benefit of an HIV microbicide is the potential to make it regularly available to 
the public. It is important to remember that “a microbicide will not be a ‘silver bullet’ for ending 
the epidemic, but rather another tool to add to existing prevention efforts”(Avert, 2010). 
Still, it is important to continue to search for any method whether it is a vaccine or microbicide 
that will be able to lower the rate the HIV pandemic is spreading.  
 
The Glucan Particle Delivery System 
Research has proven that “an important aspect of any new drug or vaccine formulation is 
a component that enhances its safety and efficacy by providing a delivery mechanism and, in the 
case of vaccines, by boosting the immune response to the antigen.” (Spiros et al., 1991).  β-
Glucans have been referred to as “biological response modifiers,” and are known for their ability 
to activate the immune system.  Applications of materials derived from glucans include the use 
of glucan particles (GP) for macrophage targeted drug delivery. (Chihara, 1992). 
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Glucan particles are hollow, porous, 2-4 µm spherical particles extracted from 
Saccharomyces cerevisia (Baker’s yeast). In order to prepare the β-Glucans, the yeast cell wall is 
treated so that the cell wall components and the soluble proteins within the yeast cell are 
removed (Figure 6). 
The glucan particles are composed primarily of β-1, 3-D-glucan and small amounts of, 
residual chitin. Encapsulation of payload molecules within glucan particles allows for protection 
and targeted delivery of the drug into cells with β-glucan cell surface receptors (dectin-1 and 
Complement Receptor 3 or CR3) such as macrophages, neutrophils and dendritic cells.(Brown, 
2001). This makes the glucan particles an efficient delivery vehicle to target cells in the immune 
system.  
Previous work has focused on developing methods to encapsulate macromolecular drugs 
(siRNA, DNA, proteins) inside glucan particles based on the “in situ layer-by-layer synthesis of 
electrostatically bound complexes caged within hollow yeast cell wall particles” as depicted in 
Figure 7 (Soto and Ostroff, 2008).  
The ability to protect and deliver drugs to macrophages, in addition to the immune 
boosting properties of glucan, makes glucan particles a suitable option to develop formulations 
containing HIV drugs as potential microbicides. The medication, in this case Nevirapine, would 
be packaged into a core inside the particle, and then would release the drugs once it was 
delivered into the body. The methods for obtaining a core that will not only contain the drug but 
release it back out is a process that in due time will hopefully be properly developed.  In the case 
of the cores made with Nevirapine. The drug would bind to a protein which would in turn bind to 
the tRNA. Various formulations using different glucan particle batches as well as different 
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substances in the core were used in order to accurately determine which ones were the most 
beneficial in trapping and releasing Nevirapine. 
 
 
Figure 6: Glucan Particles before and after removal of cell wall components (Yan et al., 2005) 
 
 
Figure 7: Yeast Glucan Particles Containing Various Cores (Soto and Ostroff, 2008) 
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PROJECT PURPOSE 
 
The effects of HIV/AIDS are far reaching, and at this point in time it seems that progress 
is being made but more must be done to ensure that the transmission of HIV is severely 
decreased.  Previous experiments using β-glucan particles have shown success in using this 
technology as a delivery vehicle for macromolecules (i.e. DNA, siRNA, proteins), and there is 
current interest to extend its use to delivery of small drug molecules.  
The main purpose of this project was to evaluate the use of glucan particles to 
encapsulate the anti-HIV drug Nevirapine. In order to successfully do this, it was first required 
that the drug was properly characterized and to evaluate the best conditions for trapping of 
Nevirapine within protein/tRNA nanoparticulate complexes. After conditions for Nevirapine 
trapping were identified, several assays were developed to measure the loading of the drug as 
part of a Nevirapine/protein/tRNA complex inside the glucan particles. After successful loading, 
the samples were examined in order to determine the release conditions from each GP nevirapine 
core formulation.  If these methods proved to work as expected, the goal would be to make sure 
the different formulations were not toxic to cells.  
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MATERIALS AND METHODS 
 
Materials: 
Reagents:  
Nevirapine (Viramune) 200 mg tablets (Boehringer Ingelheim, Ridgefield, CT). 
Ovalbumin (OVA) from chicken egg white, Bovine Serum Albumin (BSA), Human Serum 
Albumin (HSA), Ribonucleic acid from torula yeast, Type VI (tRNA), 25 kDa branched 
polyethylenimine (PEI), ethanol, acetic acid, and HPLC grade methanol were purchased from 
Sigma-Aldrich (Allenstown, PA) and used as received.  
Dulbecco’s Phosphate buffered saline (PBS) was obtained from Invitrogen (Carlsbad, CA). 
0.9% sodium chloride was purchased from Baxter Healthcare Corporation (Deerfield, IL) 
Glucan particles were available in Dr. Ostroff’s laboratory and were prepared according to 
previously published procedures (Soto and Ostroff, 2008) 
Stock solutions of OVA and BSA at 50 mg/mL in water  
Stock solution of Nevirapine at 10 mg/mL in acetic acid pH 2 
Stock solution of tRNA 1.5 mg/mL in 0.9% saline  
 
Equipment: 
Mortar with pestel,  
15 and 50 mL centrifuge tubes and 1.5 mL Eppendorf tubes 
Virtis lyophilizer (Virtis Company, Gardiner, NY)  
Nanosep 3 k Omega centrifuge filters (Pall Corporation, Ann Arbor, MI) 
96-well Costar plates with UV transparent flat bottom (Corning Inc., Corning, NY) 
Safire Tecan microplate reader (Tecan Group, Männedorf, Switzerland) 
 
Methods: 
 
Nevirapine Extraction 
The Nevirapine used throughout these experiments came from two different sources, 
which were either the pure compound or purified from commercial Viramune tablets. Since 
Nevirapine pills contain other compounds the Nevirapine had to be extracted and crystallized. 
The Nevirapine pill was crushed using a mortar and pestle and then weighed in a 50 ml 
centrifuge tube. Dilute acetic acid (50 mL, pH 2.4) was added to partially dissolve the pill. The 
sample was incubated 20 minutes, and then centrifuged for 20 min at 3,000 rpm.  The 
supernatant was collected and placed into a second 50 ml centrifuge tube. Acetic acid was added 
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again to the first tube, incubated at room temperature for 20 minutes and then centrifuged for 20 
min at 3,000 rpm as well. The second supernatant was transfer to another 50 mL tube. Both tubes 
containing the acetic acid extractions were frozen at -80⁰ C and lyophilized overnight. After the 
sample had completely dried, the Nevirapine was collected and weighed. In order to assess the 
purity, the compound was characterized by 1H-NMR, IR, and UV-Vis spectra. 
 
Binding to Different Albumin Proteins 
Stock solutions of OVA, HSA, and BSA at 50 mg protein/mL in PBS, and Nevirapine at 
17 mg/mL in HPLC grade methanol were prepared for this experiment. 1 mL of OVA-NEV, 
HSA-NEV, and BSA-NEV solutions were prepared by mixing 10 µL of Nevirapine solution 
(stock solution in MeOH) and 990 µL of 50 mg/mL protein solutions. Nevirapine control 
solution was prepared by mixing 10 uL of Nevirapine stock solution in methanol and 990 uL of 
PBS.  Additional a blank solution of 1% MeOH/99% PBS solution was prepared as control. 
The UV absorbance of stock solutions of Nevirapine, OVA, BSA, and HSA were 
measured as well as mixtures of Nevirapine with each of the albumin proteins (Nev-OVA, Nev-
BSA, and Nev-HSA).  250 µl of each solution was added to labeled 3k centrifugal ultrafiltration 
tubes. These samples were then centrifuged for 20 min at 3,000 rpm. The volume of the filtrate 
was measured and all the tubes were adjusted to the same final volume. Then 150 µl of each of 
the filtrates were transferred to a 96-well plate and the absorbance was measured at 315 nm.  
 After the absorbance had been taken, 250 µl of 1% MeOH/99% PBS solution was added 
to each of the tube, and then the samples were centrifuged through 3 k centrifugal filters at 3,000 
rpm for 20 minutes. The volume was measured, and then adjusted in all the tubes and then 150 
µl was transferred to a 96 well plate. The absorbance of each sample was taken again at 315 nm. 
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The protein/Nevirapine solution retained in the filter was also processed for measurement of 
Nevirapine absorption at 315 nm. 
 
Effect of tRNA-HSA polyplex formation on Nev-HSA binding 
Prior to beginning this experiment, fresh tRNA solutions were made in PBS at 
concentrations of 1 mg/mL, 5 mg/mL and 10 mg/mL. A sample of tRNA solution (750 µL) was 
added to a tube containing 250 µL of a HSA-Nevirapine sample. A control sample was prepared 
by adding PBS to another tube containing HSA-Nevirapine.  These tubes were incubated at room 
temperature for 20 minutes and then placed in a centrifuge for 5 minutes at 10,000 rpm. 250 µL 
of each solution was transferred to labeled 3k centrifugal filters and spun for 20 minutes at 3,000 
rpm. The filtrate was transferred and measured. Each filtrate was placed in a new Eppendorf tube 
and labeled “wash 1”. 250 µL of 1% MeOH in PBS was transferred to the 3k centrifugal tubes 
which were spun again for 20 minutes at 3,000 rpm again. The same process was repeated to 
transfer the filtrate and was labeled “wash 2” for each sample.  The volumes of all the tubes were 
adjusted to be the same volume and then 150 µL of the filtrate was placed in a 96-well plate. The 
absorbance was then taken at 315 nm to measure Nevirapine concentration. 
 
Loading of Nevirapine inside Glucan Particles 
Three methods were evaluated for trapping of Nevirapine within glucan particles. The 
first method required sequential loading of Nevirapine, protein and tRNA. The second approach 
consisted of co-loading a Nevirapine/protein mixture followed by trapping with tRNA. Finally, 
protein/tRNA cores were prepared in glucan particles and evaluated for Nevirapine binding. 
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- Method A. Sequential loading of core components: 
Prior to loading inside glucan particles, solutions of BSA and OVA were prepared in 
water with concentrations of 50 mg/mL. A 0.1M solution of acetic acid was prepared and the pH 
was adjusted to 2. This solution was used to prepare a 10 mg/mL Nevirapine solution. Empty 
glucan particles (5 mg) were used and 25 µL of the Nevirapine solution was added. Control 
samples were also set up using 25 µL of acetic acid and no Nevirapine. These samples were 
mixed and incubated for two hours at room temperature. After incubation, the samples were 
lyophilized over night. An additional 25 µL of acetic acid was then added to each sample, and 
then incubated for 1-2 hours (acetic acid push) and then the samples were again lyophilized 
overnight. 
 OVA or BSA (25 µL) was added to the samples. The serum albumins were allowed to 
penetrate the glucan particles for two hours on ice and then the samples were lyophilized. The 
samples were treated with 25 µL of water (water push), incubated for 2 hours at 4 C and 
lyophilized. 
 After this step the indicated amounts of tRNA were added to the tubes and then the 
particles were collected through centrifugation. The supernatants were also collected in labeled 
Ep-tubes and frozen for later analysis. The particles in the pellet were then re-suspended in 70% 
ethanol, sonicated then incubated for thirty minutes. The particles were washed three times with 
saline and then finally re-suspended in 1 mL of saline. The samples were sonicated, counted, and 
then adjusted to 1x10e8 particles/mL and stored at -20⁰ C. 
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- Method B. Co-loading of Nevirapine/protein mixture and subsequent trapping with tRNA 
A solution of HSA (495 μL of 50 mg/mL in PBS) and Nevirapine (5 μL of 17 mg/mL in 
methanol) was prepared and added to a sample of GP (5 μL of HSA/Nev mixture/mg particle). 
The mixture was thoroughly mixed and incubated for two hours at hours at 4 °C. tRNA (250 μL 
of  10 mg/mL) was added and the particles allowed to swell for 10 minutes, sonicated and then 
incubated at room temperature for an additional 30 min. The particles were collected by 
centrifugation, and the supernatants collected in labeled Eppendorf tubes and processed for 
measurement of unbound Nevirapine. Particle loading was carried out with sterile solvents and in 
sterile conditions to eliminate the sterilization step with 70% ethanol. Samples were finally 
washed three times with 0.9% saline, particle number counted with a hematocytometer, and 
particle dilutions were prepared with a concentration of 1x108 particles/mL and frozen 
 
 - Method C. Binding of Nevirapine to GP-protein/tRNA cores 
In this method protein/tRNA cores were first synthesized inside glucan particles and used 
for Nevirapine binding. A solution of HSA, BSA or OVA (50 mg/mL) was mixed with the 
particles (5 μL/ mg particles) and incubated for 2 hours at 4°C. The sample was lyophilized and 
5 μL of water/mg particles was added (water push step). The sample was incubated for an hour 
and lyophilized. A solution of tRNA (final protein: tRNA ratio of 15) was added to the particles, 
the sample was sonicated and incubated for 30 minutes. The GP-protein/tRNA cores were 
washed three times in 0.9% saline, counted and diluted to 1x108 particles/mL and stored frozen. 
An assay was set up to evaluate Nevirapine binding by titrating Nevirapine concentration from 0 
to 2.5 μg/mL. Samples were set up containing 10 μL of 1x108 particles/mL (1x106 particles), the 
Nevirapine solution in methanol and PBS to bring the final volume to 100 μL. The Nevirapine 
was prepared in methanol and the final concentration of methanol in the samples containing 
23 
 
particles was 1%. The samples were incubated at room temperature for 2 hours. Then the 
samples were centrifuged, and the supernatants carefully transferred to another tube and 
processed to measure unbound Nevirapine by UV absorption at 315 nm. UV assay for 
quantitative analysis of Nevirapine 
In all experiments, Nevirapine was quantified by measuring absorption at 315 nm of the 
unbound Nevirapine collected after separation from the particles by centrifugation. The 
Nevirapine removed from washing the particles was also quantified. The total amount of 
Nevirapine from the first supernatant and washes was used to indirectly estimate the percentage 
of Nevirapine bound within the particles. All samples measured by UV assay were processed by 
addition of spectrophotometric grade methanol to adjust the concentration of methanol to 90% 
v/v.  This allowed for precipitation of tRNA and proteins that would interfere with UV 
absorption measurements. The samples were centrifuged, and the supernatant transferred to 96-
well plates to measure the absorbance. In all experiments, control samples of PBS, tRNA, and 
proteins were also treated with methanol to assure that the interferents were being removed prior 
to the UV measurements.  
 
UV Assay for Quantitative Analysis of Nevirapine 
In all experiments, Nevirapine was quantified by measuring absorption at 315 nm of the 
unbound Nevirapine collected after separation from the particles by centrifugation. The 
Nevirapine removed from washing the particles was also quantified. The total amount of 
Nevirapine from the first supernatant and washes was used to indirectly estimate the percentage 
of Nevirapine loaded into the particles. All samples measured by UV assay were processed by 
addition of spectrophotometric grade methanol to adjust the concentration of methanol to 90% 
v/v.  This allowed for precipitation of tRNA and proteins that would interfere with UV 
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absorption measurements. The samples were centrifuged, and the supernatant transferred to 96-
well plates to measure the absorbance. In all experiments, control samples of PBS, tRNA, and 
proteins were also treated with methanol to assure that the interferents were being removed prior 
to the UV measurements.  
 
Evaluation of Nevirapine Release from GP-Nevirapine Formulations 
 In order to determine whether Nevirapine was being released from the protein/tRNA 
cores two primary methods were used. The first method used pepsin treatment to determine the 
amount of Nevirapine released. 100 μL of each sample being tested were transferred to labeled 
Ep-tubes. The samples were centrifuged and 90 μL of the supernatant were removed. 90 μL of 
pepsin was then added to the samples, and then the samples were sonicated and incubated 
overnight at room temperature. After the particles had been incubated, they were sonicated again, 
and 90 μL of the supernatant was transferred to another tube which was then centrifuged. 75 μL 
of the supernatants were transferred into a 96-well plate and the absorbance was measured at 315 
nm. The samples were also incubated in methanol, HCl, high salt concentrations and EDTA.  
 The second method for evaluating the Nevirapine release involved feeding the samples to 
3T3-D1 cells. This cell line is capable of phagocytosing glucan particles via the dectin-1 glucan 
receptor.10 μL of the samples of interest were added to 90 μL of saline. Samples containing 
empty particles as well as samples of pure saline were used as controls as well. Each sample was 
then mixed with 250 μL of DMEM and transferred to wells containing the 3T3-D1 cells. The 
cells were incubated overnight, and then the medium was collected in labeled Ep-tubes.  The 
remaining cells were then treated with trypsin and fixed with formalin. 
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Evaluation of GP-Nevirapine Toxicity to 3T3-D1 Cells 
 In order to evaluate Nevirapine toxicity, the release of the drug from the protein/tRNA 
cores in glucan particles was assessed. Cores that contained various formulations of Nevirapine, 
proteins and tRNA were fed to 3T3-D1 cells. 10 μL of the samples of interest were added to 90 
μL of saline. These were then combined with 250 μL of DMEM and transferred to wells 
containing the 3T3-D1 cells. The cells were incubated overnight and then the medium was 
collected, transferred to a new plate and then frozen. The remaining cells were then washed with 
PBS and fixed with formalin. 
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RESULTS 
 
Nevirapine Extraction 
Nevirapine was obtained from the commercial drug formulation Viramune by an acetic 
acid extraction. Nevirapine has high solubility in aqueous solutions at low pH, while most of the 
excipients are insoluble in aqueous solvents. The insoluble excipients include microcrystalline 
cellulose, lactose croscarmellose sodium, povidone, colloidal anhydrous silica, purified talc, and 
magnesium stearate which make up the pill.  Analysis of the extracted compound by NMR 
(Figure-8), IR, and UV-Vis demonstrated that the compound obtained was relatively pure, and 
suitable for use in the glucan particle encapsulation assays without further purification. 
Nevirapine was extracted from the commercial pills with a 99.6% yield. 
 
Figure 8: 1H -NMR of Nevirapine extracted from Viramune pills 
 
The 1H-NMR results (Figure 8) showed characteristic bands of Nevirapine which 
matched up with the results obtained from testing a known sample of Nevirapine.  Figure 9 also 
shows the UV/Vis spectra of Nevirapine in methanol. A maximum absorption peak at 280 nm 
was measured. Based on the peaks obtained from the NMR it is possible to identify which 
protons from the structure correspond with each chemical shift. Around 0.45 and 0.95 the shifts 
are caused by the CH groups on the cyclopropane. In the picture of Nevirapine (Figure 10) these 
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hydrogens, which are mirroring CH2 groups, are identified as 31, 32, 33, and 34. The next 
visible shifts occur at the methyl group around 2.1 and correspond with the hydrogens 27, 28, 
and 29. The final shift of interest from the NMR is at 3.2, and this corresponds with the final part 
of the cyclopropane group and is identified as H30. 
 
Figure 9: UV-Vis spectra of Nevirapine in methanol 
 
 
 
 
Figure 10: Nevirapine Structure With Labeled  
Hydrogens (Hannongbua et al., 2001) 
 
 
0.0000
0.1000
0.2000
0.3000
0.4000
0.5000
0.6000
0.7000
0.8000
240 340 440 540
Ab
so
rb
an
ce
nm
28 
 
Nevirapine Binding 
It is known that Nevirapine binds effectively to human serum albumin (HSA) (Bocedi et 
al., 2004). Encapsulation of proteins (OVA and BSA) within GPs has been achieved by 
formation of nanoparticulate cores assembled by electrostatic interactions between protein and 
tRNA (Soto and Ostroff, 2008).  Based on the developed protocols for protein encapsulation 
within GP and the ability of Nevirapine to bind HSA, it was decided to develop methods for 
Nevirapine encapsulation as part of a protein/tRNA core. The efficiency of Nevirapine binding to 
different albumin proteins and the effect of protein precipitation with tRNA on Nevirapine 
retention within the protein/nev complex was evaluated to determine optimal conditions (protein, 
nevirapine and tRNA concentrations) for GP loading. 
Mixtures of the different proteins with Nevirapine were filtered using 3 kDa centrifugal 
filters to separate unbound Nevirapine from the  protein/Nevirapine complex that is retained by 
the filter due to its high molecular weight. The absorbance of the processed filtrate and retentate 
was measured at 315 nm to quantify Nevirapine.  A wavelength of 315 nm was chosen for this 
assay as the Nevirapine presents a high absorption and protein or tRNA interference is minimal. 
Background absorption from the other core components is higher at 254 nm or at the maximum 
absorption wavelength of Nevirapine (280 nm). Additionally, absorption at 315 nm has been 
used in HPLC assays that are expected to be implemented to quantify Nevirapine bound to GP 
samples.  
The results shown in Figure 11 indicate that human serum albumin was most effective in 
binding the Nevirapine at 83%. Bovine serum albumin and ovalbumin also bound Nevirapine 
with 54% and 37% efficiency and were used for the preparation of GP-Nevirapine formulations. 
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Figure 11: Nevirapine Binding to Different Albumin Proteins. 
 
The second part of this experiment to optimize Nevirapine loading was the evaluation of 
tRNA interaction with the protein/Nevirapine complex. Specifically, tRNA was titrated to 
determine the optimal amount of tRNA required to precipitate the protein and retain the drug 
(Nevirapine) as part of the complex.     
The results (Figure 12) show that at low concentrations of tRNA (1 mg/mL) the amount 
of Nevirapine retained is greater than at the higher concentrations of tRNA.  At only 1 mg/mL 
tRNA the percent Nevirapine bound is almost 80% but when the tRNA concentration is 
increased to 5 mg/mL or 10 mg/mL, the percent bound is only around 40%, nearly half the 
amount as the lower concentration.  tRNA at lower concentrations do not form a precipitate with 
the proteins. Therefore, the lowest concentration of tRNA (1 mg/mL) capable to precipitate the 
protein is essential and will be extremely important once we load the drug into the glucan 
particles.      
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Figure 12: Effect of tRNA Concentration on Nevirapine  
Bound to the Nevirapine/HSA/tRNA Nanoparticle Complex. 
 
 
Nevirapine Loading into Glucan Particles 
As indicated in the previous section (Materials and Methods), three methods were 
evaluated for encapsulation of Nevirapine within glucan particles.  Essential to keeping the drug 
and the protein inside the glucan particle was the protein’s interaction with tRNA.  Since tRNA 
will precipitate the protein, the Nevirapine will remain bound as long as the tRNA concentration 
is kept low, around 1mg/mL, as discovered in the previous experiment.   
 In the first instance of the loading (method A), a 10 mg/mL sample of Nevirapine in 
acetic acid was used.  A half of the hydrodynamic volume (10 µL/mg GPs) of the Nevirapine 
solution was added to the glucan particles and allowed to incubate for two hours before it was 
frozen and lyophilized. Nevirapine was added twice to maximize drug loading before addition of 
the protein and final precipitation with tRNA.   
The amount of Nevirapine bound in the cores was indirectly determined by measuring the 
amount of unbound Nevirapine collected in the supernatant after particle centrifugation and 
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subsequent particle washings. Sequential loading of the core components (Method A) was used 
to prepare formulations of Nevirapine with OVA and BSA. 
 
Figure 13: Method B of Loading Protein/tRNA/Nevirapine  
Cores into Glucan Particles 
 
In the co-loading method (method B) solutions of HSA/Nevirapine were loaded into 
glucan particles followed by tRNA precipitation of the HSA/Nevirapine complex (Figure 13). 
The amount of Nevirapine bound was also quantified by measurement of the unbound 
Nevirapine in the supernatants. Figure 14 shows the results as percentage of Nevirapine trapped 
inside glucan particles for the best formulations obtained with each of the three albumin proteins. 
The results of the loading experiments were pretty conclusive.  It was determined that the glucan 
particle core that best trapped the Nevirapine was built using a Nevirapine-HSA-tRNA core.  
This core yielded a loading efficiency of 62%.  The BSA-tRNA core trapped the Nevirapine at 
41% and the OVA-tRNA core yielded 29% efficiency.  The results of this experiment are 
expected.  The HSA was the best for trapping the Nevirapine and this result was not surprising 
due to the fact that the HSA had the best binding efficiency with drug. 
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Figure 14: Nevirapine Loading in Glucan Particles 
 
 
Finally, Nevirapine binding was evaluated using GP-protein/tRNA formulations (Method 
C) (Figure 15). Nevirapine binding to these protein core formulations was evaluated by titrating 
the amount of Nevirapine incubated with a constant amount of particles (1x106 particles). The 
results shown in Figure 16 demonstrate that all particles containing a protein core efficiently 
bound Nevirapine. The negative controls (empty glucan particles or particles containing a 
tRNA/PEI core) show less Nevirapine binding as most the compound was removed after 
washing the samples. 
 
Figure 15: Method C of Loading Protein/tRNA/Nevirapine Cores into Glucan Particles 
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Figure 16: Nevirapine Binding to GP-Protein/tRNA Formulation. 
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DISCUSSION 
 
Through our project we developed methods to successfully trap Nevirapine inside glucan 
particles.  Glucan particles have been efficiently used to encapsulate macromolecules like DNA 
and siRNA by formation of nanoparticulate materials assembled by electrostatic interactions 
between the anionic nucleic acids and cationic trapping polymers like polyethylenimine (PEI). 
There is a growing interest to extend the applicability of the glucan particle delivery technology 
to encapsulate small drug molecules. Our project was focused on the encapsulation of the HIV 
drug Nevirapine for the potential use of GP-Nevirapine formulations as a topical HIV 
microbicide.  Glucan particles have been used to trap protein molecules such as Ovalbumin and 
Bovine Serum Albumin (BSA) by formation of protein/tRNA nanoparticulate complex. It is also 
known that Nevirapine binds efficiently to albumin proteins, specifically to human serum 
albumin. Taking into consideration the binding ability of Nevirapine to HSA and the possibility 
of forming protein/tRNA cores within GP it was determined that the best approach to attempt 
trapping of Nevirapine is by formation of Nevirapine/albulimin-protein/tRNA cores. 
To assess the best conditions for formation of these cores, the binding of Nevirapine to 
different albumin proteins was measured by UV. As shown in Figure 10, HSA efficiently binds 
the drug confirming previous studies that have reported binding of Nevirapine to HSA with 70% 
higher efficiency. It was found that OVA and BSA also bind Nevirapine and subsequently these 
proteins were also evaluated for Nevirapine trapping inside GPs.  A critical step in the formation 
of Nev/protein/tRNA cores is the precipitation of the Nevirapine/protein complex upon addition 
of tRNA without significant loss of Nevirapine. Typically GP-protein/tRNA cores are prepared 
using a high ratio of protein: tRNA (1:10). However this high ratio of tRNA was found to 
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displace Nevirapine from the complex. The tRNA titration results (Figure 11) showed that a 
protein: tRNA ratio of 1 allows for effective precipitation of the protein/Nevirapine complex 
without significant loss of Nevirapine. A lower tRNA: protein ratio does not effectively forms a 
tRNA/protein precipitate.  
Loading of Nevirapine within GP and trapping into a tRNA/protein core was investigated 
by three methods. The first method was the sequential loading of the drug components. Efficient 
adsorption of payloads into glucan particles was achieved by soaking dry particles in half of the 
hydrodynamic volume of the particles. The wet sample is then lyophilized before addition of the 
next component of the core formulation. This method guarantees maximum adsorption of each 
component. The final compound added to this formulation is the trapping polymer (tRNA) that 
forms the stable nanoparticulate complex trapped within the particles. This method was applied 
to form Nevirapine/protein/tRNA cores with OVA and BSA. The results of Figure 12 show that 
the best formulations contain less than 50% of the input Nevirapine.  
In the second method, the drug and protein were co-loaded into the glucan particles and 
then tRNA was added to precipitate the protein/Nevirapine complex. In this method the 
lyophilization steps were not carried out as it is possible that the cycles of drying and re-
suspending the samples had a negative effect on Nevirapine solubility and its interaction with the 
re-dissolved protein resulting in poor Nevirapine retention inside the particles. This method 
allows for efficient trapping of the HSA/Nevirapine as shown in Figure 12.  
The final method evaluated to trap Nevirapine was the use of glucan particles containing 
a pre-formed protein/tRNA core. If the binding sites of the protein are still available after 
complex formation with tRNA, it should be possible to absorb the drug in a similar fashion to the 
LbL assembly of plasmid DNA or siRNA onto glucan encapsulated cationic cores. To guarantee 
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that Nevirapine would bind, the protein/tRNA cores were prepared using the minimum tRNA: 
protein ratio that allows for protein core formation. The results from Figure 13 show that the 
cores were effective in binding Nevirapine with more than 50% binding at different drug 
concentrations.  
 Three methods to successfully trap the Nevirapine have been developed and these 
methods need to be optimized.  For Methods A and B, the concentration of Nevirapine was 
constant the entire time.  The last loading experiment that built a protein-tRNA core and then 
allowed the Nevirapine to be absorbed was the only experiment where the concentration of 
Nevirapine was varied.  In order to optimize the loading, the concentration of Nevirapine should 
be varied.  It was discovered that the 2.5 µg of Nevirapine yielded a higher trapping efficiency 
than the 0.25 µg, but varying the concentrations will allow for the optimal concentration to get 
the best binding rate.   
 The amount of Nevirapine bound to the particles was indirectly determined by a UV 
assay. Characterization of the samples still requires optimization. The best method that will 
provide a direct measurement of bound Nevirapine is the use of HPLC. Different GP-Nevirapine 
formulations were processed to (1) facilitate release of the drug from the formulation by 
incubating the samples with pepsin to degrade the protein, different salt concentrations, pH, and 
solvents to release the drug from the cores, and (2) treatment of the whole particle sample with 
DMSO to dissolve the particles and analyze the final mixture by HPLC. Future work will focus 
on optimization of HPLC protocols to quantify total Nevirapine bound in GPs and Nevirapine 
release. In Figure 13, the only result that was slightly skewed from what was expected came 
from the cores that contained only glucan particles. Since there was no Nevirapine in the samples 
there shouldn’t have been any Nevirapine found when evaluated by UV spectrum. This could 
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have been caused by improper washing or inefficiency when washing the samples. This also 
proves that another method to quantitate the Nevirapine contents of the samples is necessary in 
order to properly examine the cores. 
Different GP-Nevirapine formulations were evaluated for toxicity effect on the murine 
fibroblast cell line NIH3T3-D1. Particles were fed at ratios of 1, 3.3, 10 and 33 particles/cell. 
After analyzing the results from this experiment, the Nevirapine formulations had no visible 
effects or toxicity on the cells.  
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FUTURE WORK 
 
 After performing experiments on Nevirapine extraction, binding, and loading, it is clear 
that this drug has the potential to be used to create a successful HIV microbicide. The methods 
developed have allowed for Nevirapine to be trapped inside HSA-tRNA cores with an optimal 
binding efficiency greater than 70%. In the future, the next step needed to continue progressing 
forward is a more in depth analysis of the samples by HPLC. The binding efficiency can be 
assessed in a much more exact manner through the use of HPLC. By creating a concentration 
gradient using samples containing known amounts of Nevirapine, it will be possible to determine 
exactly what is binding within the cores. Different concentrations of Nevirapine can also be used 
to optimize loading. The rate of Nevirapine released from the particles is also a key factor. If the 
Nevirapine is not properly released from the cores, then the Nevirapine may have trouble being 
delivered to macrophages and Langerhans cells, which is the ultimate goal of this microbicide. 
The rate needs to be determined in order to make sure that this is a viable method of preventing 
HIV infection. 
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APPENDIX A 
 
 
Tube HSA-Nevirapine µL Trapping 
Polymer 
µL 
1 250 PBS 750 
2 250 1 mg/ml tRNA 750 
3 250 5 mg/ml tRNA 750 
4 250 10 mg/ml tRNA 750 
1. Prepare the following mixtures:  
    10 uL of Nevirapine in MeOH + 990 uL PBS  
    1 mL of HSA-Nev solution by mixing 10 uL of Nevirapine solution (stock solution in 
MeOH) and 990 uL of protein solution 
    1, 5, and 10 mg/mL tRNA in PBS  
2.  Measure 250 uL of HSA-Nev. Add indicated amount of tRNA or PBS 
3.  Incubate 20 min at room temperature  
4. Centrifuge samples 5 min at 10 rpm  
5.  Transfer 250 uL of sample to labeled 3 k centrifuge filters 
6.  Centrifuge samples 20 min at 3000 rpm  
7.  Carefully transfer filtrate to labeled Ep tubes and measure total volume 
8.  Add 250 uL of 1%MeOH/99% PBS solvent mixture to each tube. 
     Centrifuge samples 20 min at 3000 rpm  
9.  Carefully transfer filtrate to labeled Ep tubes (wash 1) and measure total volume 
10.  Repeat steps 6-7 to collect wash#2  
11.  Adjust volumes of all Ep tubes to same final volume 
12. Transfer 100 uL to 96-well plate  
13. Measure Abs @ 315 and calculate % of unbound Nevirapine 
 
tube mg GP µL 0.1 M aa protein µL protein mg/ml tRNA µL tRNA 
1 5 0 50 mg/ml OVA 25 1.5 500 
2 5 0 50 mg/ml BSA 25 1.5 500 
3 5 25 50 mg/ml OVA 25 1.5 500 
4 5 25 50 mg/ml BSA 25 1.5 500 
1. Use 5 mg YGP in  Ep tubes  
2. Prepare 0.1 M acetic acid. Check pH and adjust to pH 2 
3. Prepare a 10 mg/mL solution of Nevirapine in acetic acid 
4. Add 25 uL of Nevirapine solution to GP. Add acetic acid to control samples. Mix w/blunt 
pipette tip until wet 
5. Incubate 2 hours at room temperature 
6. Freeze, lyophilize 
7. Add 25 uL 0.1 M acetic acid. Incubate 1-2 hours 
8. Freeze, lyophilize 
9. Prepare 50 mg/mL OVA in water, 50 mg/mL BSA in water 
10. Add 25 uL of OVA or BSA solution to GP-Nevirapine (5 uL 50 mg/mL OVA/BSA /mg 
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GPs) 
11. Mix w/blunt pipette tip until wet and allow OVA or BSA to penetrate GP for 2 hours on ice 
12. Freeze/lyophilize 
13.  Carry out water wash by adding 25 ul saline to tubes. Incubate 2 hrs 4C. 
14   Add indicated volume of tRNA at indicated concentration in  0.9% saline at 50C 
15.  Allow to swell for 10 minutes at 50C, sonicate to single particles, allow to coat for 20 
minutes 
16.  Collect particles by centrifugation.  Collect supers into labeled Ep-tubes.  Freeze for 
Nevirapine analysis 
17.  Wash 3X in 0.9% saline - resuspend by sonication - Collect supers into labeled Ep-tubes. 
Freeze for Nevirapine analysis 
18.  Resuspend in 70% ethanol - sonicate, incubate at least 30 min 
19.  Wash 3X in 0.9% saline - resuspend by sonication  Resuspend tubes in 1 ml saline  
20.  Sonicate, count, adjust aliquot to 1x10^8 particles/ml.   
21.  Store tubes at -20C 
 
Tube mg GP Loading solution µL mg/mL tRNA µL tRNA 
1 5 HSA-NEV 25 1 250 
2 5 HSA 25 1 250 
3 5 HSA-NEV 25 1 250 
4 5 HSA 25 1 250 
5 0 HSA-NEV 25 1 250 
6 0 HSA 25 1 250 
 
1.  Prepare a 0, 0.001, 0.01, and 0.1 mg/mL Nevirapine solution in PBS  
2.  Measure UV absorbance @ 315 nm of Nevirapine solutions before setting up experiment 
3.  Mix indicated amounts of PBS, Nevirapine and particles  
4.  Incubate samples for 1 hour    
5.  Centrifuge samples. Carefully transfer 90 uL of SN to 96-well plate  
6.  Add 90 uL of PBS to each tube. Sonicate sample, vortex and transfer to 96-
well plate       
7.  Measure UV absorbance @ 315 nm 
   
1. Prepare the following mixtures: 
    10 uL of Nevirapine in MeOH + 990 uL PBS 
    1 mL of OVA-Nev and BSA-Nev solutions by mixing 10 uL of Nevirapine solution (stock 
solution in MeOH) and 990 uL of protein solution 
2.  Measure UV absorbance @ 315 of stock solutions of mixtures of OVA/Nev, HSA/Nev, and 
BSA/Nev, and Nev solution in 1% MeOH 
3. Transfer 250 uL of indicated solutions to labeled 3 k centrifugal filters 
4.  Centrifuge samples 20 min at 3000 rpm 
5.  Carefully transfer filtrate to labeled Ep tubes and measure total volume 
6.  Add 250 uL of 1%MeOH/99% PBS solvent mixture to each tube. 
     Centrifuge samples 20 min at 3000 rpm 
7.  Carefully transfer filtrate to labeled Ep tubes (wash 1) and measure total volume 
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8.  Repeat steps 6-7 to collect wash#2 
9.  Adjust volumes of all Ep tubes to same final volume 
10. Transfer 100 uL to 96-well plate 
11. Measure Abs @ 315 and calculate % of unbound Nevirapine 
 
 
